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Maine Medical Center's AIDS Consultation Service Spring 1996 
FDA Committee Recommends 
Approval of Viral Load Tests 
Full FDA approval is expected soon on the use of quantitative HIV plasma viral load 
measurement for assessing prognosis in HIV infection and for monitoring the response 
to antiviral therapy . 
Currently, HIV viral load or the concentration of HIV RNA strands in plasma is 
measured either by quantitative polymerase chain reaction (QT-PCR) or by a technique 
called branched DNA signal amplification (bDNA). A third means of measuring viral 
load nucleic acid sequence-based amplification (NASBA) is under study . 
The value of HIV viral load determinations in predicting progression of HIV disease was 
demonstrated by Mellors et al using banked sera from the Multi-Center AIDS Cohort 
Trial. Patients with high CD4 counts had markedly variable rates of progression to 
AIDS and the rate of progression was predicted by the level of viral load. While CD4 
count provides an indication of the overall status of the immune system, the viral load 
test provides an index of actual viral activity . Patients may have high or low CD4 
counts and have any level of viral load. Those patients with HIV viral loads > 105 
HIV/RNNml of plasma had rapid progression, whereas those with levels of <10,000 had 
slower than average progression. Most clinicians believe that early treatment of the 
subset of patients at high risk for rapid progression may prove helpful. 
Recent research trials also support the use of viral load in the assessment of an 
individual's response to antiviral therapy. O'Brien et al demonstrate the utility of a 
baseline level at the time of initiation of treatment followed by a second sample after 
4 weeks of therapy . A drop in viral load of 0.5 log (three-fold) or greater is considered 
indicative of a good response to treatment. With the availability of this measure, it is 
hoped that patient's treatment can be individualized for maximum effectiveness. 
Several caveats are in order when using viral loads. They should not be obtained during 
intercurrent viral infections or within one month of immunizations as viral load may be 
transiently elevated. Two baseline determinations are often recommended before starting 
antiviral therapy. In addition, for serial comparison, the same method (ie. quantitative 
PCR or bDNA) should be used each time for a patient. Viral load may vary within an 
individual by up to 0.3 log with repeat testing, so differences of <0.5 log are not 
considered reliable. EDT A rather than heparin anticoagulant tubes should be used for 
sample collection. 
Viral load measurements should be obtained every 3-4 months to assess the continued 
effectiveness of antiviral therapy . A substantial rise in viral load during therapy suggests 
that antiviral resistance may be developing, and should lead to consideration of other 
therapeutic options. 
Millers JW et al : Quantitation of HIV-1 RNA in plasma outcome after seroconversion 
Ann Int Med 199.5:.573-.579 
O'Brien et al : Changes in plasma HIV-1 RNA and CD4 counts and risk of progression to AIDS . 
NEJM 334: 426-432, 1996. 
Research News 
HIV Cofactor Discovered 
A membrane protein that serves as a key 
cofactor necessary for the binding of HIV 
to CD4 cells has been isolated by a 
research team from the N.l.H . (Science 
272 : 809-810, 1996 ). This protein, called 
fusion, has been the object of a scientific 
search for over a decade. Researches 
believe that discovery of this co-factor 
will lead to new avenues of investigation 
of the pathogenesis of HIV, and may well 
lead to interventions that target virus-cell 
binding. 
Maternal Viral Load 
Several studies presented at the 3!:l! 
Conference on Retroviruses address the 
relationship of maternal viral load to 
vertical transmission of HIV. One study, 
recently published, found a clear 
relationship, with no maternal - fetal 
transmission at a viral load of 25 ,000 . 
High viral loads were the best predictor of 
mother to child transmission. AZT 
treatment of the mother resulted in an 
eight-fold drop in viral load. 
However, a second study was not so clear. 
In this report, most of the 151 pregnant 
woman received AZT treatment, but the 
medical vial load associated with 
transmission (-5 ,000 copies/ml) was only 
slightly higher than the median level 
among nontransmitters (2 ,000 c9pies). 
Secondly, reports from ACTG 076 
revealed no substantial significant 
differences between viral load among 
transmitters and nontransmitters, although 
no transmission occurred among the 
women with undetectable levels of virus. 
It was noted in this study that the 
effectiveness of AZT in pregnancy may 
be in large part due to the treatment of the 
infant after birth, as intrapartum exposure 
is thought to be of greater risk than the 
prepartum experience. 
Update : Provisional Public Health Service Recommendations for 
Chemoprophylaxis After Occupational Exposure to HIV 
A Public Health Service (PHS) interagency working group (comprised of representatives of CDC, the Food and Drug Administration 
(FDA), the Health Resources and Services Administration, and the National Institutes of Health) has recently (MMWR, June 7, 1996) updated 
the PHS's recommendations on management of occupational exposure to HIV. Its findings and recommendations on postexposure prophylaxis 
(PEP) are as follows 1: 
Background Data Used: 
ZDV - Postexposure prophylaxis (PEP) was associated with a decrease of approximately 79% in the risk for HIV seroconversion 
after percutaneous exposure to HIV-infected blood in a case-control study among health-care workers (HCW)2. In a prospective trial in which 
ZDV was administered to HIV-infected pregnant women and their infants, a direct effect of ZDV prophylaxis on the fetus and/or infant may 
have contributed to the observed 67% reduction in prenatal transmission•. 
The average risk for HIV infection from all types of reported percutaneous exposures to HIV-infected blood in 0.3%3. In the case-
control study2, risk was increased for exposures involving: 1- a deep injury to the HCW; 2- visible blood on the device causing the injury; 
3- a device previously placed in the source patients vein or artery; or 4- a source patient who died as a result of AIDS within 60 days 
postexposure (and therefore was presumed to have a high titer of HIV)2. Identification of these risk factors suggests that the risk for HIV 
infection exceeds 0.3% for percutaneous exposures involving a larger blood volume and/or higher HIV titer in blood. The risks after volume 
and/or higher HIV titer in blood. The risks after mucus membrane and skin exposures to HIV-infected blood [ on average, approximately 
0.1 % and <0.1 %, respectively (7)], probably also depend on volume of blood and titer of HIV. The risk is probably higher for skin contact 
that is prolonged, involves an area that is extensive or in which the skin integrity is visibly compromised, and/or involves a higher titer. 
Although information about the potency and toxicity of antiretroviral drugs is available from studies of HIV-infected patients, it is 
uncertain to what extent this information can be applied to uninfected persons receiving PEP. In HIV-infected patients, combination therapy 
with ZDV and 3TC has greater antiretroviral activity than AZT alone8. Adding a protease inhibitor provides even greater increases in 
antiretroviral activity; among protease inhibitors, lndinivir (IDV) is more potent than Saquinavir and appears to have fewer drug interactions 
and short-term adverse effects than Ritonavir8. Few data exists to assess possible long-term toxicity resulting from use of these drugs in 
persons not infected with HIV. 
In currently recommended doses, ZDV PEP usually is tolerated well be health-care workers3• The toxicity of other antiretroviral 
drugs in persons not infected with HIV has not been well characterized. 
Recommendations 
The PHS recommendations are stated as provisional because they are based on limited data regarding efficacy and toxicity of PEP 
and risk for HIV infection after different types of exposure. The recommendations are prefaced with the following provisions: 
Because most occupational exposures to HIV do not result in infection transmission; potential toxicity must be carefully considered when 
prescribing PEP. When possible, these recommendations should be implemented in consultation with persons have expertise in antiretroviral 
therapy and HIV transmission. Changes in drug regimens may be appropriate, based on/actors such as the probable antiretroviral drug 
resistance profile of HIV from the source patient; local availability of drugs; and medical conditions, concurrent drug therapy, and drug 
toxicity in the exposed worker. These recommendations were not developed to address nonoccupational (eg. sexual) exposures. 
1. Chemoprophylaxis should be recommended to exposed workers after occupational exposures associated with the highest risk for 
HIV transmission. For exposures with a lower, nonnegligible risk, PEP should be offered, balancing the lower risk against the use of drugs 
having uncertain efficacy and toxicity. For exposures with negligible risk, PEP is not justified (Table 1). Exposed workers should be 
informed that a)knowledge about the efficacy and toxicity of PEP is limited; b) for agents other than ZDV, data are limited regarding toxicity 
in persons without HIV infection or who are pregnant; and c) any or all drugs for PEP may be declined by the exposed worker. 
2. At present, ZDV should be considered for all PEP regimens because ZDV is the only agent for which data support the efficacy of 
PEP in the clinical setting, 3TC should usually be added to ZDV for increased antiretroviral activity and activity against many ZDV-resistant 
strains. A protease inhibitor (preferably IDV because of the characteristics summarized in this report) should be added for exposures with 
the highest risk for HIV transmission (Table 1). Adding a protease inhibitor also may be considered for lower risk exposures if ZDV-resistant 
strains are likely , although it is uncertain whether the potential additional toxicity of a third drug is justified for lower risk exposures. For 
HIV strains resistant to both ZDV and 3TC or resistant to a protease inhibitor, or if these drugs are contraindicated or poorly tolerated, the 
optimal PEP regimen is uncertain; expert consultation is advised. 
3. PEP should be initiated promptly, preferably within 1-2 hours postexposure. Although animal studies suggest that PEP probably 
within 1-2 hours postexposure. Animal studies suggest that PEP probably is not effective when· started later than 24-36 hours postexposure 
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, the interval after which there is no benefit from PEP for humans is undefined. Initiating therapy after a longer interval (e.g., 1-2 weeks) 
may be considered for the highest risk exposures; even if infection is not prevented, early treatment of acute HIV infection may be 
beneficial 10• The optimal duration of PEP is unknown; because 4 weeks of ZDV appeared protective2, should probably be administered for 
4 weeks, if tolerated. 
4. If the source patient or the patient's HIV status is unknown, initiating PEP should be decided on a case-by-case basis, based on the 
exposure risk and likelihood of HIV infection in known or possible source patients. If additional information becomes available, decisions 
about PEP can be modified. 
5. Workers with occupational exposures to HIV should receive follow-up counseling and medical evaluation, including HIV antibody 
Continued on Page 3 
Use of HIV RNA Viral Load Measures 
Indications for use of viral load: 
1. Determine prognosis in early disease 
2. Assessment of adequacy of antiviral therapy 
Currently Available Methods 
Quantitative PCR Branched DNA 
AmQlification 
(Roche) (Chiron) 
Advantages High sensitivity (to <100 Higher reliability 
copies RNA I ml) 
Disadvantages Labor - intensive Lower sensitivity (to 
<10,000 copies RNA I ml) 
Cost Approx. $200.00 Approx. $200.00 
Interpretative Use of Viral Load 
1) For monitoring therapy, obtain 1-2 baseline levels and then repeat at approximately 1 month 
after initiation or change of therapy. 
2) Consider a change every > 0.5 log (three-fold) as significant. 
3) Use same method for serial monitoring every 3-4 months. 
4) Attempt to keep viral load as low as possible (ie. undetectable) 
Table 1. Provisional Public Health Service recommendations for 
chemoprophylaxis after occupational exposure to HIV, by type 
of exposure and source material - 1996. 
Type of Exposure Source Material An tiretroviral Antiretroviral 
Prophylaxis Regimen 
Percutaneous Blood 
Highest Risk Recommended ZDV plus 3TC plus 
IDV 
Increased Risk Recommended ZDV plus 3TC ± 
IDV 
No Increased Risk Offer ZDV plus 3TC 
Fluid containing 
visible blood, 
other potentially Offer ZDV plus 3TC 
infectious fluid or 
tissue 
Other body Fluid Not Offer 
(e.g., urine) 
Mucous Membrane Blood Offer ZDV plus 3TC ± 
IDV 
Fluid containing 
visible blood, 
other potentially Offer ZDV + 3TC 
infectious fluid or 
tissue 
Other body Fluid Not Offer 
(e.g., urine) 
Skin, 
increased risk Blood Offer ZDV plus 3TC ± 
IDV 
Fluid containing 
visible blood, 
other potentially Offer ZDV + 3TC 
infectious fluid or 
tissue 
Other body Fluid Not Offer 
(e.g., urine) 
Corrected Maine AIDS Care, Winter 1996 
Principles of Protease Inhibitor Use 
1. Start with highest appropriate dose and avoid dose adjustment if possible. 
2. Use in combination with other agents. 
3. Be aware of drug interactions ( see other side of insert). 
New Antiviral Agents & Combinations 
Class Drug Usual Dosage Side Effects Effective Regimens 
RT Inhibitors 
Nucleoside AZT 200 mgtid Bone marrow suppression AZT 
(Zidovudine) Myopathy AZT+DDI 
GI symptoms AZT+DDC 
AZT+ 3TC 
All regimens with or without 
a protease inhibitor. 
DOI 200 mg bid Pancreatitis DOI 
( didanosine) GI intolerance DDI+AZT 
Neuropathy DDI + D4T (Z?) 
All regimens with or without 
a protease inhibitor. 
DDC 0.75 mgtid Pancreatitis (rare) DDC 
( deoxycytidine) Neuropathy DDC +AZT 
Oral I esophageal ulcers All regimens with or without 
a protease inhibitor. 
D4T 40 mg bid Neuropathy D4T 
(Stavudine) D4T +DOI(?) 
3TC 150 mg bid GI intolerance 3TC+AZT 
(Lamivudine) Neutropenia (rare) AZT + 3TC + Protease 
Inhibitor 
Non-Nucleoside Delavirdine 400 mgtid Rash Delavirdine + AZT 
(available through GI intolerance Delavirdine + DOI 
compassionate use Delavirdine +AZT+ DOI 
only) orDDC 
Protease Inhibitors 
Saquinavir 600 mg tid GI intolerance Saquinavir + 1 or 2 RT 
(with food) Drug interactions inhibitors 
Ritonavir 600 mg bid GI intolerance Ritonavir + l or 2 RT 
(with food) Drug interactions inhibitors 
lndinavir 800 mg q8hours GI intolerance AZT + 3TC + lndinavir 
(without food) Nephrolithiasis (2-5%) lndinavir + l or 2 RT 
Drug interactions inhibitors 
Analgesic 
Cardiovascular 
(Antiarrhythmic) 
Antimycobacterial 
Cardiovascular 
Potential Drug Interactions - Ritonavir 
(Data on lndinavir Not Available) 
Avoid Alternative Treatment 
meperidine (Demora!) acetaminophen (Tylenol) 
piroxicam (Feldene) .. aspmn 
propoxyphene (Darvon) oxycodone (Percodan) 
amiodarone ( Cordarone) 
encainide (Enkaid) 
flecainide (T ambocor) 
propafenone (Rythmol) 
quinidine 
rifabutin (Mycobutin) clarithromycin (Biaxin) 
ethambutol (Myambutol) 
bepridil (V ascor) 
( calcium channel blocker) 
Cold & Allergy 
(antihistamine) 
Gastrointestinal 
Psychotropic 
(antidepressant) 
Psychotropic 
(sedative/hypnotic) 
astemizole (Hismanal) loratadine (Claritin) 
terfenadine (Seldane) 
cisapride (Propulsid) 
bupropion (Wellbutrin) fluoxetine (Prozac) 
desipramine (Norpramin) 
alprazolam (Xanax) temazepam (Restoril) 
clorazepate (Tranxene) lorazepam (Ativan) 
diazepam (Valium) 
estazolam (Prosam) 
fluroepam (Dalmane) 
midazolam (Versed) 
triazolam (Halcion) 
zolpidem (Ambien) 
If you have questions regarding the use or 
side effects of Protease Inhibitors call the 
AIDS Consultation Service 
Treatment Information Line@ 
1-800-871-2701 
I 
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Viral Load: A Patients Perspertive, 
by Michael Martin 
For over eight years, the amount of time I've known I'm HIV-positive, I've 
depended on the results of CD4 counts to assess where I stand with my HIV infection. 
The actual number of CD4 cells and their percentages have been and still are my 
markers for evaluating how my immune system is doing. If the numbers went up, and 
they often did, then I could be self-satisfied that the virus was being held at bay. If the 
numbers went down, and they often did, then I could convince myself that I was having 
a bad day, maybe I had a cold or was overly tired, and the next test would be better. 
Or if they dropped, I could say that the drop was really statistically insignificant and 
safely assuage myself until the next count. In other words, I had a handle, intellectually 
and emotionally, on whatever results I got. 
So along comes the new viral load test which monitors actual viral amounts and 
activity. A test that some think actually predicts future health. To say that I was 
resistant to this new test, at first, is a bit of an understatement. Without being able to 
say why, my initial reaction (for a couple of months) was that I didn't want to take this 
test. When I figured out my resistance, it really amounted to this, a viral load is 
significantly different medically and psychologically from getting a CD4 count. A CD4 
count is an indirect way of trying to tell how the virus is working in my body. A CD4 
count is about the strength of my immune system and its ability to fight infections. If 
my CD4 count drops and my immune system is therefore weakened, then I will be more 
open to opportunistic infections. I have had years to get comfortable with CD4 counts. 
A viral load measures actual amounts of virus in the blood, a direct look at my HIV 
virus, a direct indicator of how much virus I have at any given time. One more reality 
step closer to the nasty HIV virus. In other words, another layer between me and my 
virus is being exposed and I wasn't too thrilled about it. 
Still, I relented and finally got a viral load test done and, lo and behold, the 
world did not end, the sky did not fall, and neither did my arches. On the other hand, 
my viral load count was significantly higher than my doctor liked, (normally he's so easy 
to please!}, and although, at the very same time I got significantly good news about a 
jump in my CD4 count, the mixed results managed to ruin about half a day. On any 
other day, a jump from 340-500 in my CD4 count would have left me feeling very 
happy, even cocky. But the higher viral load count of 36,600 was my headache that 
day. In the end I reminded myself that it was a first count, a new experience for me and 
that like CD4 counts at the beginning of my infection, I would get a better handle on 
viral loads with experience. That I will understand and withstand the results of viral 
loads better in the future. And, right now, a count of 36,600 is not devastating news. 
It could be better or it could be a lot worse. 
Of course, I took counsel from my doctor, my favorite nurse, and Project Inform 
and I understand that viral loads are a new and significant tool in deciding treatment 
strategies and will become as routine as CD4 counts in the future. They also respond 
more rapidly than CD4 counts to changes in the body. With my new drug study 
regimen of U90, AZT, and 3TC, the next viral load should show a drop. That's my 
hope, anyway. It also helps that I have good health insurance and am involved in a drug 
study that provides my medications for free. I try to count my blessings, and keeping 
a handle on the spiralling costs of even routine HIV care is important. 
In the meantime, I can only do what I can do, which is to take my medicines 
faithfully, get plenty of rest, watch out for undue stress, and enjoy the fact that I've not 
had any opportunistic infections associated with HIV. And to remember to enjoy life. 
Every day fretting over this or that not-as-perfect-as-I-would-like test result is time lost 
enjoying mild weather, the company of friends and family, the satisfaction of freshly 
mowed grass, and the joy of four cats named Fanny, George, Sandy, and Tigger. In 
short, I can worry or I can be content. As long as I can, I'll take contentment. 
I remember the words of Abraham Lincoln when he said, 11 Most people are 
about as happy as they want to be. 11 
Continued from page 2 
tests at baseline and periodically for at least 
6 months postexposure (e.g., 8 weeks, 12 
weeks, and 6 months), and should observe 
precautions to prevent possible secondar 
transmission 1• If PEP is used, drug 
toxicity monitoring should include a 
complete blood count and renal and hepatic 
chemical function tests at baseline and 2 
weeks after starting PEP. If subjective or 
objective toxicity is noted, dose reduction 
or drug substitution should be considered 
with expert consultation, and further 
diagnostic studies may be indicated. 
Health-care workers who become infected 
with HIV should receive appropriate 
medical care. 
6. Beginning July 15, 1996, health 
care providers in the United States ar 
encouraged to enroll all workers who 
receive PEP in an anonymous registr 
being developed by CDC, Glaxo Wellcome 
Inc., and Merck & Co., Inc., to assess 
toxicity (telephone [888)737-4448). 
Unusual or severe tox1c1ty from 
antiretroviral drugs should be reported to 
the manufacturer and/or the Food and Drug 
Administration (telephone [800] 332-1088). 
Updated information about HIV PEP will 
be available beginning in early 1997 from 
the Internet at CDC home page 
(http://www.cdc.gov.); CDC's fax 
information service, telephone (404)332-
4565 (Hospital Infections Program 
Directory); the National AIDS 
Clearinghouse, telephone (800)458-5231 ; 
and the HIV/AIDS Treatment Information 
Service, telephone (800)448-0440. 
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Maine AIDS Plan 
by Martha Piscuskas 
A recently published resource synthesizes much of what Maine's response to HIV looks like, and points the way to the future. The 
Maine AIDS Plan: A Blueprint for Action, a product of the Maine AIDS Alliance, is an accessible reference and action guide created 
by and for Maine people. 
Says Sandy Putnam, Maine Medical Center's AIDS Consultation Service Nurse Coordinator and a Plan founder, "Since this 
disease truly effects all of us, right from the start our intent was to create a very accessible, user-friendly document. I believe we've 
succeeded". And users all over the state confirm that this is "an excellent resource". 
One section was specifically developed my and for Maine health care providers, with some surprising findings. 
Recommendations are interspersed throughout the chapter, and several pages are devoted to local and national resources specifically 
for physicians and other health care providers and consumers. 
This is not a small book, though its 270 pages are bound in a 3-ring binder for easy photocopying (which is encouraged), and 
tabs make it easy to flip through and find specific sections. Fact sheets and brief chapters are designed for quick reading. Photos, 
sidebar interviews, and graphics also contribute to its utility for the general public. 
Over 200 individuals, including people with HIV, providers, advocates, educators, employers, and policy makers contributed. 
"This is not a top-down plan," explains Martha Piscuskas, director of the project, which was funded through CDC prevention monies 
and private donations. "The research and recommendations came directly from the experience of people in the field" . 
The Maine AIDS Plan is free to non-profits, one per agency; all AIDS Service Organizations, and many schools and 
libraries throughout the state have copies. Individuals may also purchase copies for a minimal fee . For more information, contact 
the Maine AIDS Plan, 112 State Street, Augusta, ME 04330 Telephone (208)622-2962. 
Maine Medical Center's 
AIDS Consultation Service 
22 Bramhall Street 
Portland ME 04102 
AIDS Cases 
World AIDS Cases 
U.S. AIDS Cases 
U.S. AIDS Deaths 
4,500,000• 
513,486 
319,849 
Reported through 12/31/96 by CDC 
Maine AIDS Cases 720 
Maine AIDS Deaths 347 
Reported through March 31, 1996 
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